Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest and fastest-growing pharmaceutical companies in the Indian Pharmaceutical Market (IPM). Founded in 1991, Mankind Pharma commenced operations in 1995 and has been engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others, as well as several consumer healthcare products.

Driven by the Philosophy of Quality, Affordability and Accessibility, Mankind aspires to deliver integrated solutions to all valued customers with a strong focus on research and development, innovation, and customer-centricity. Thus, making Mankind a trusted and preferred partner in India’s healthcare journey.

The company has 30 manufacturing facilities in India, manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 660 scientists.

Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. Their success stems from a robust portfolio that has played an integral role in outpacing IMP growth. It has also resulted in volume-led growth for Mankind. The company has transferred its Over-the-Counter (OTC) business undertaking to its wholly owned subsidiary, Mankind Consumer Products Private Limited (MCPPL). Mankind Pharma’s consumer products portfolio includes several category-leading brands that include Manforce, HealthOK, Prega News, AcneStar, Unwanted and Gas-O-Fast across categories such as wellness, hygiene and personal care products.

Mankind Pharma Limited has completed the transaction to acquire 100% stake in Bharat Serums and Vaccines Limited (BSV). This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women’s health and fertility drug market alongside access to other high entry barrier products care including immunoglobulins, recombinant products supported by established complex R&D tech platforms.